title: [A tailored approach to radiofrequency ablation of hepatocellular carcinoma and its outcome].
abstract: OBJECTIVE
  To evaluate the effectiveness of a tailored approach to radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC).
  
  
  METHODS
  Ultrasound-guided percutaneous RFA was performed in 274 tumors of 228 patients located at liver periphery, including 59 near the bowel, 115 near the diaphragm, 54 near the gallbladder, and 46 near the liver surface. The tumor sizes ranged 1.2-7.0 cm [mean (3.7 +/- 1.2) cm]. A tailored treatment strategy was established for tumors in different locations. Contrast-enhanced CT was performed one month later to evaluate the early necrosis rate of the treated tumors.
  
  
  RESULTS
  Early tumor necrosis rate was 91.6% of the peripherally located HCC, including 91.5% of the tumors near the bowel, 90.4% near the diaphragm, 92.6% near the gallbladder, and 93.5% near the liver surface. Local tumor recurrence rates were 8.5%, 9.6%, 7.4%, and 6.5% for tumors near the bowel, diaphragm, gallbladder, and liver surface, respectively. The 1-, 2-, and 3-year survival rate of this group were 82.3%, 62.9%, and 53.7%, respectively. Major complications occurred in 3.3% of the treatment sessions, including haemorrhage (n = 2), nearby structure injury (n = 6), and needle tract seeding (n = 4).
  
  
  CONCLUSIONS
  The tailored approach to RFA provides a promising treatment option for refractory peripherally located HCC with satisfactory tumor necrosis rate and low complication rate.
authors: Department of Ultrasound, Beijing Cancer Hospital and Institute, School of Oncology, Peking University, Beijing 100036, China. minhuachen@bjcancer.org
authors: Min-Hua
authors: MH
authors: Chen
authors: Wei
authors: W
authors: Yang
authors: Kun
authors: K
authors: Yan
authors: Jin-Yu
authors: JY
authors: Wu
authors: Ying
authors: Y
authors: Dai
authors: Wen
authors: W
authors: Gao
authors: Hui
authors: H
authors: Zhang
authors: Wei
authors: W
authors: Wu
mesh_terms: D000008:Abdominal Neoplasms / Q000556:secondary / Q000601:surgery*; D006528:Carcinoma, Hepatocellular / Q000556:secondary / Q000601:surgery*; D017115:Catheter Ablation / Q000009:adverse effects; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000601:surgery*; D009364:Neoplasm Recurrence, Local; D016896:Treatment Outcome